DXR Daxor Corp.

Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100® Study in Hospitalized Patients With COVID-19

Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100® Study in Hospitalized Patients With COVID-19

COVID-19 Investigation Commences at NYU Langone Health with Daxor’s Blood Volume Analysis Technology

NEW YORK, July 15, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of a multicenter prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health in New York City is the first site to enroll patients under the leadership of Jan Bakker, MD, PhD.

“Institutions have been using and collecting data on the BVA-guided care of COVID-19 patients since the onset of the pandemic,” said Michael Feldschuh, CEO and President of Daxor Corporation. “A multicenter trial is essential to understanding COVID-based volume derangements. We are encouraged by the initial application of the BVA to improve care and outcomes and are confident that the BVA will continue to help physicians detect and manage the significant underlying volume derangements suffered by COVID patients in the ICU.”

Jonathan Feldschuh, Chief Scientific Officer of Daxor, stated, “Accurate volume assessment allows for individualized care, ensuring circulatory integrity and optimal tissue perfusion. Our BVA technology provides clinicians with precise volume measurement superior to commonly used indirect estimates. The BVA also offers insights into patients’ capillary leak rate, which has been shown to be an early prognostic indicator in critically ill patients. In addition, the use of the blood volume to optimize treatment has been shown to improve outcomes in other clinical settings. We expect to announce additional study sites in the coming weeks.”

Daxor’s FDA-cleared diagnostic instrument used in critical care can help guide treatment, as the BVA-100 measures patients’ blood, plasma and red cell volume and calculates the ideal blood volume that the patient should have, with statistics showing deviations from the patient-specific ideal. The BVA is the only test that provides a unique measure of capillary permeability via its albumin tracer, an important insight into COVID-19 pathophysiology. This study aims to show the implications of COVID as an endothelial disease utilizing this measure.

In a randomized control trial (RCT) published in 2011 in the journal Shock, patients at a Level-1 trauma center ICU suffering predominantly from ARDS/sepsis/septic shock/hemorrhagic shock who received BVA-guided care showed significant benefits including a 66% lower mortality rate (P<0.03), reducing mortality from 24% to 8%. Analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at .

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner, CORE IR

516-222-2560

EN
15/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Daxor Corp.

 PRESS RELEASE

Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technol...

Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the opening of a new BVA program at a premier Florida healthcare center in the Tampa Bay region. This expansion integrates Daxor's innovative blood volume analysis (BVA) testing across the facility's inpatient and outpatient care programs, revolutionizing fluid management precision and enhancing treatment ...

 PRESS RELEASE

Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signal...

Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance Daxor’s Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant expansion of its blood volume analysis (BVA) capabilities in three new hospitals. This growth is accelerated by the widespread adoption of Daxor's ezBVA Lab service – a cutting-edge, CLIA-certified facility delivering precise, on-demand blood volume analysi...

 PRESS RELEASE

Daxor Corporation to Exhibit at the 45th International Society for Hea...

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, will attend the 45th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions. This premier event gathers approximately 3,500 international specialists in advanced heart and lung dise...

 PRESS RELEASE

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedA...

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025 WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation Oak Ridge, TN, April 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’25 Conference being held at the Renaissance Orlando at SeaWorld in Orlando, FL from April 24-26, 2025. The Cardiovascular Transforum conference unites ca...

 PRESS RELEASE

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failu...

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival Precise Volume Measurement Prior to Discharge Identifies Mortality Risk Oak Ridge, TN, April 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced compelling new data presented at the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. Research from The Minneapolis Heart Institute Foundation® and Allina Health Minneapolis Heart Institute® demonst...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch